Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Drug Type
- Biotech
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
- Conditions
- Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05445882
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Bintrafusp Alfa Program Rollover Study
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2025-04-29
- Target Recruit Count
- 32
- Registration Number
- NCT05061823
- Locations
- 🇯🇵
Saitama Medical University International Medical Center, Hidaka-shi, Japan
🇺🇦Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy, Lutsk, Ukraine
🇷🇺BHI of Omsk region "Clinical Oncology Dispensary" - PARENT, Omsk, Russian Federation
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 47
- Registration Number
- NCT05005429
- Locations
- 🇪🇸
ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaStage IIIC Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Unresectable Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04971187
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
- Conditions
- Transitional Cell CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 49
- Registration Number
- NCT04878250
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
- Conditions
- Advanced Soft-tissue SarcomaMetastatic Soft-tissue Sarcoma
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 80
- Registration Number
- NCT04874311
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷Institut Paoli Calmette, Marseille, France
🇫🇷Institut Curie, Paris, France
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast AdenocarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Triple-Negative Breast CarcinomaStage IVA Lung Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Stage IVB Lung Cancer AJCC v8Hematopoietic and Lymphoid Cell NeoplasmMetastatic Melanoma
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT04789668
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
- Conditions
- Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast AdenocarcinomaMetastatic HER2 Negative Breast Adenocarcinoma
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04756505
Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 3
- Registration Number
- NCT04727541
- Locations
- 🇩🇪
Universitätsklinikum RWTH Aachen - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Aachen, Germany
🇩🇪Universitätsklinikum Frankfurt - Medizinische Klinik 1, Frankfurt, Germany
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
- Conditions
- Oropharyngeal CancerVaginal CancerNeck CancerAnal CancerColon CancerHuman PapillomavirusCervical CancerVulvar CancerHPVPenile Cancer
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04708470
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.